Orphan Drugs and Rare Diseases Conference 2018

SMi Group17 - 18 October, London, UK.
Patients with rare diseases cannot continue to be overlooked because of costly therapies and have the same rights to treatment as any other patient. At this year's Orphan Drugs and Rare Diseases conference, organised by SMi Group and taking place in London, industry experts will address the opportunities and challenges within the rare disease treatment field.

Keep up to date with the industry and to learn from expert speaker panel, bringing you important new case studies and reports on this year’s relevant topics.

Highlights in 2018

  • Discuss the pricing and reimbursement of orphan drugs
  • Understand the challenges of patient recruitment and patient-centric research
  • Hear the MHRA's perspective on benefit-risk assessment in rare diseases
  • Explore the clinical development of orphan drugs for rare disease
  • Gain insight into potential synergies between regulators and assessors

Speakers include

  • Carina Schey, Researcher, University of Groningen
  • Xavier Ortega, Project Manager, Rare Diseases, Minoryx
  • Nigel Nicholls, Director and Country Manager UK/Ireland, BioMarin Europe Ltd
  • Yolanda Barbachano, Senior Statistical Assessor, MHRA
  • MichaleBouskila-Chubb, Head of Business Development, Healx

Interactive Workshop (16 October) run by JG Zebra Consulting will be looking into question: "Working together for HTA in rare diseases - a step too far or the way forward?"

Orphan Drugs and Rare Diseases conference this year is set to inspire the international rare diseases community by exploring synergies between regulators, health and technology assessors

For further details, please visit:
http://www.orphandrugs.co.uk

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Novartis presents first-of-its-kind algorithm-base…

Novartis today announced results from a validation study of the innovative, algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool a...

Trastuzumab deruxtecan demonstrated clinically-mea…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab ...

Genetic therapy heals damage caused by heart attac…

Researchers from King's College London have found that therapy that can induce heart cells to regenerate after a heart attack. Myocardial infarction, more commonly known ...